Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 440Precursor Cell Lymphoblastic Leukemia-Lymphoma 238Hematologic Neoplasms 216Leukemia, Lymphocytic, Chronic, B-Cell 186Myelodysplastic Syndromes 160Leukemia 129Lymphoma 91Lymphoma, Non-Hodgkin 82Leukemia, Myelogenous, Chronic, BCR-ABL Positive 73Multiple Myeloma 69Recurrence 59Leukemia, Myelomonocytic, Chronic 56Neoplasms 53Leukemia, Biphenotypic, Acute 48Burkitt Lymphoma 48Myeloproliferative Disorders 46Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 43Lymphoma, Large B-Cell, Diffuse 42Lymphoma, Mantle-Cell 41Hodgkin Disease 39Lymphoma, Follicular 34Lymphoma, B-Cell 33Lymphoma, B-Cell, Marginal Zone 27Waldenstrom Macroglobulinemia 26Leukemia, B-Cell 26Anemia, Refractory, with Excess of Blasts 25Primary Myelofibrosis 24Myelodysplastic-Myeloproliferative Diseases 21Leukemia, Myeloid, Chronic-Phase 19Hematologic Diseases 19

Interventions

venetoclax 1pevonedistat 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypereosinophilic Syndrome × Other hematologic neoplasm × 90 days × Clear all
NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡